All Inventions from NCI

  • Methods of Producing Effective T-cell Populations Using Akt Inhibitors
    •
       Ref: E-013-2016 | Updated: Dec 5, 2017 | NCI
  • Metastatic ovarian cancer mouse models and cell lines for preclinical studies
    •
       Ref: E-069-2012 | Updated: Nov 20, 2017 | NCI
  • Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics
    •
       Ref: E-351-2013 | Updated: Nov 14, 2017 | NCI
  • Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia
    •
       Ref: E-014-2017 | Updated: Oct 27, 2017 | NCI
  • Combination Therapy for Prostate and Breast Cancer
    •
       Ref: E-257-2014 | Updated: Oct 27, 2017 | NCI
  • Clinical Outcome Predictors for Mantle Cell Lymphoma
    •
       Ref: E-131-2016 | Updated: Oct 25, 2017 | NCI
  • A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays
    •
       Ref: E-001-2014 | Updated: Oct 23, 2017 | NCI
  • Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles
    •
       Ref: E-277-2016 | Updated: Oct 23, 2017 | NCI
  • Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer
    •
       Ref: E-275-2014 | Updated: Oct 23, 2017 | NCI
  • Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy
    •
       Ref: E-078-2012 | Updated: Oct 11, 2017 | NCI
  • Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases
    •
       Ref: E-159-2009 | Updated: Oct 10, 2017 | NCI
  • A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences
    •
       Ref: E-067-2017 | Updated: Oct 6, 2017 | NCI
  • Immunogenic Peptide from NGEP Protein for Developing Prostate Cancer Vaccines
    •
       Ref: E-042-2009 | Updated: Oct 4, 2017 | NCI
  • Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors
    •
       Ref: E-245-2016 | Updated: Sep 29, 2017 | NCI
  • T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-Associated Pathologies
    •
       Ref: E-166-2014-0 | Updated: Sep 12, 2017 | NCI
  • Use of Heterodimeric IL-15 in Adoptive Cell Transfer
    •
       Ref: E-132-2016 | Updated: Sep 7, 2017 | NCI
  • Biomarker for Predicting Taxane Chemotherapy Outcome
    •
       Ref: E-191-2009 | Updated: Aug 9, 2017 | NCI
  • Module to Freeze and Store Frozen Tissue
    •
       Ref: E-173-2015 | Updated: Aug 3, 2017 | NCI
  • Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers
    •    Ref: E-091-2009 | Updated: Jun 29, 2017 | NCI
  • Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors
    •
       Ref: E-115-2015 | Updated: Apr 18, 2017 | NCI
  • Silicone Hydrogel Support Structures that Mimic Tissue Vasculature for Cell Culturing
    •
       Ref: E-070-2013 | Updated: Mar 30, 2017 | NCI
  • Biomarker signature development: microRNAs for biodosimetry
    •
       Ref: E-066-2015 | Updated: Mar 6, 2017 | NCI
  • Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy
    •
       Ref: E-013-2012 | Updated: Mar 6, 2017 | NCI
  • Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics
    •
       Ref: E-025-2015 | Updated: Feb 13, 2017 | NCI
  • Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic
    •
       Ref: E-130-2016 | Updated: Feb 13, 2017 | NCI
  • Griffithsin-Based Anti-viral Therapeutics with Improved Stability and Solubility
    •
       Ref: E-065-2015 | Updated: Feb 13, 2017 | NCI
  • Anti-bacterial Treatments Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway
    •
       Ref: E-278-2014 | Updated: Jan 18, 2017 | NCI
  • Optical Microscope Software for Breast Cancer Diagnosis
    •
       Ref: E-286-2012 | Updated: Sep 30, 2016 | NCI
  • Virus-Like Particles That Can Deliver Proteins and RNA
    •
       Ref: E-264-2011 | Updated: Sep 30, 2016 | NCI
  • High-Affinity Rabbit Monoclonal Antibodies for Cancer Treatment
    •
       Ref: E-198-2012 | Updated: Sep 6, 2016 | NCI
  • Modulating Chemotherapeutic Cytotoxicity
    •
       Ref: E-296-2011 | Updated: Sep 6, 2016 | NCI
  • Novel Fusion Proteins for HIV Vaccine
    •
       Ref: E-256-2012 | Updated: Sep 6, 2016 | NCI
  • Phosphodiesterase as a target for cancer therapeutics
    •
       Ref: E-199-2010 | Updated: Sep 6, 2016 | NCI
  • Nitric Oxide-Releasing Polymers for Wound Healing
    •
       Ref: E-157-2012 | Updated: Sep 5, 2016 | NCI
  • 89Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and Associated Methods
    •
       Ref: E-080-2014 | Updated: Aug 31, 2016 | NCI
  • Cancer Therapeutic Based on T Cell Receptors Designed to Regiospecifically Release Interleukin-12
    •
       Ref: E-170-2009 | Updated: Aug 31, 2016 | NCI
  • GTF2I Mutations as a Genetic Marker for Prognosis of Thymic Malignancies
    •
       Ref: E-109-2014 | Updated: Aug 31, 2016 | NCI
  • Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness
    •
       Ref: E-269-2009 | Updated: Aug 31, 2016 | NCI
  • Increased Therapeutic Effectiveness of PE-Based Immunotoxins
    •
       Ref: E-263-2011 | Updated: Aug 31, 2016 | NCI
  • Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents
    •
       Ref: E-167-2010 | Updated: Aug 31, 2016 | NCI
  • Synthetic lipopeptide inhibitors of RAS oncoproteins
    •
       Ref: E-293-2010 | Updated: Aug 31, 2016 | NCI
  • Use of Anti-CD47 Antibodies for the Treatment of Cancer
    •
       Ref: E-263-2014 | Updated: Aug 31, 2016 | NCI
  • Background-Free Fluorescent Nanodiamond Imaging
    •
       Ref: E-261-2012-0 | Updated: Feb 21, 2013 | NCI
  • Quantitative Determination Of Marker Proteins In Complex Mixtures
    •
       Ref: E-013-2005-0 | Updated: Dec 1, 2007 | NCI

    Pages


    Displaying 201 - 244 of 244

    Office of Technology Transfer, Office of Intramural Research, National Institutes of Health

    6011 Executive Blvd, Suite 325, Rockville, MD 20852 | Phone: 301-496-7057